Tracon shares data from phase 2 trial for glioblastoma treatment

Betsy Goodfellow | June 12, 2024 | News story | Medical Communications |  Oncology, Tracon Pharmaceuticals, clinical tria, clinical trial, glioblastoma 

Tracon Pharmaceuticals has announced the publication of its phase 2 clinical data for its DNA damage repair inhibitor drug candidate, TRC102, for the treatment of patients with glioblastoma in Clinical Cancer Research.

The article is titled ‘Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT’ and focuses on the use of TRC102 in combination with Temodar chemotherapy in patients with recurrent glioblastoma.

The drug was evaluated in a phase 2 trial in combination with Temodar in 19 patients with progressive or recurrent glioblastoma following surgical resection, Temodar and external beam radiotherapy. The trial demonstrated an extended survival in two patients, both of whom also demonstrated significantly enriched signatures of DNA damage response (DDR), chromosomal instability and cellular proliferation by RNA sequencing prior to beginning treatment with Temodar and TRC102.

James Freddo MD, chief medical officer of Tracon Pharmaceuticals, commented: “We believe that the data generated to date provides a strong rationale for studying TRC102 in combination with Temodar and radiotherapy in newly diagnosed patients with malignant glioma. The Clinical Cancer Research publication supports prior data published in Cancer Cell that patients whose cancers demonstrate activation of DDR pathways may be particularly sensitive to the pharmacologic effects of TRC102.”

Betsy Goodfellow